US3925173A - Electrocatalytic hydrogenation process - Google Patents

Electrocatalytic hydrogenation process Download PDF

Info

Publication number
US3925173A
US3925173A US466172A US46617274A US3925173A US 3925173 A US3925173 A US 3925173A US 466172 A US466172 A US 466172A US 46617274 A US46617274 A US 46617274A US 3925173 A US3925173 A US 3925173A
Authority
US
United States
Prior art keywords
process according
steroid
aromatic
finely divided
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US466172A
Other languages
English (en)
Inventor
Klaus Junghans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of US3925173A publication Critical patent/US3925173A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0085Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0088Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092Alkenyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J15/00Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • CCHEMISTRY; METALLURGY
    • C25ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25BELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00Electrolytic production of organic compounds
    • C25B3/20Processes
    • C25B3/25Reduction

Definitions

  • the process of this invention is directed to selectively hydrogenating unsaturated steroids having a complicated structure to stereochemically uniform compounds.
  • steroid compounds having at least one carbon-carbon multiple bond which is isolated or conjugated with an aromatic ring is electrocatalytically hydrogenated in an acidic solution employing cathode whose surface is a finely divided metal hydrogenation catalyst.
  • Starting steroids for the process of this invention are those steroids having a complicated structure, i.e., steroids having at least one carbon-carbon multiple bond which is either isolated or conjugated with an aromatic ring and which is hydrogenatable to a mixture of stereoisomers, e.g., when hydrogenated in a conventional manner with zinc dust and acetic acid or with hydrogen and palladium on charcoal catalyst.
  • the process of this invention is conducted by depositing the hydrogen required for the hydrogenation electrolytically on a cathode whose surface is a finely divided metal hydrogenation catalyst.
  • a cathode whose surface is a finely divided metal hydrogenation catalyst.
  • All that is required is that the metal be in finely divided hydrogenation catalytically active form.
  • Suitable metals are those of Subgroup VIII of the periodic table, e.g., iron, cobalt, nickel, palladium, osminum, iridium and platinum, es-
  • pecially suitable are palladium, nickel or platinum.
  • the finely divided metal is applied in finely divided form on an ainert cathode support of any desired density in a convention manner; this support can be formed, for example, of copper, gold, ABS (acrylonitrile-butadienestyrene) or other solid synthetic resin, platinum or pal ladium. Its shape is not important.
  • a strip or a plate can be used.
  • Preferred cathodes are Raney nickel and palladinated platinum.
  • Preferred electrodes are platinum, palladium, platinated titanium, graphite, ferrite, manganese(lV)-dioxide and lead(IV)-dioxide.
  • finely divided metal as used herein means that the catalytically active metal deposited on the surface of the cathode support exhibits an effective surface area at least ten times greater than the geometric surface area of the cathode.
  • the starting steroid is reduced in an acidic solution, i.e., having a pH of less than 7, preferably from about 5 to 0.
  • Suitable as the solvents are all the solvents conventionally used for hydrogenations.
  • Preferred are solvents which are miscible with water, e.g., lower alcohols of l8 carbon atoms, e.g., methanol, ethanol, propanol, isopropanol and butanol, polyhydric alcohols, e.g., ethylene glycol, propylene glycol and glycerin, dialkyl ethers, e.g., diethyl ether, cyclic ethers, e.g., tetrahydrofuran and dioxane; chlorinated hydrocarbons, e.g., chloroform and dichloroethylene; acid derivatives, e.g., dimethylformamide and acetonitrile; and, last but not least, water by itself or in a mixture with
  • the starting steroid can be dissolved in the preacidified solvent or the pH of the solvent can be rendered acidic after the steroid is dissolved therein.
  • a preferred reaction solvent is a lower-alkanol, alone or in admixture with a cyclic ether, mixed, in a volume ratio of from about l0:l to about l:1, with aqueous, e.g., about l-IO percent hydrochloric, hydrobromic or sulfuric acid or with concentrated hydrochloric or sulfuric acid.
  • the electrolytic hydrogenation can be conducted from below room temperature to the boiling point of the reaction mixture, e.g., from about 20-80 C.
  • the reaction is continued preferably until all of the starting steroid has been hydrogenated, usually for about l-24 hours, e.g., 2-8 hours.
  • the solvent is preferably acidified with a mineral acid, e.g., hydrochloric acid, perchloric acid, phosphoric acid, sulfuric acid or fluoboric acid, which serves simultaneously as the electrolyte.
  • a mineral acid e.g., hydrochloric acid, perchloric acid, phosphoric acid, sulfuric acid or fluoboric acid
  • Organic acids e.g., acetic acid, trifluoroacetic acid and propionic acid, are suitable.
  • the amount of acid added can be varied within wide limits and has no effect on the hydrogenation per se.
  • the acid e.g., acetic acid, for example, can optionally also be employed as the hydrogenation solvent. It will be apparent to those skilled in the art that sufficient electrolyte must be present in the solution to provide the desired current density.
  • the electrolysis is advantageously conducted in a divided cell, i.e., one in which the anode and cathode chambers are separated from each other by a porous material, such as, for example, clay, porous glass, or an ion exchanger membrane.
  • a porous material such as, for example, clay, porous glass, or an ion exchanger membrane.
  • a divided cell has the advantage that the electrolytic reaction which occurs at the cathode is not influenced by the reaction at the anode.
  • the electrolysis is effected according to conventional methods. It is not critical that the current or the potential be maintained constant. However, it is advantageous to operate at a constant current.
  • the magnitude of the amperage can be varied within wide limits, e.g., from 1 mA to 50 A, depending on the geometric surface of the electrodes and the desired rate of electrolysis. However, it is desirable to employ a current density of 0.01 1O A/cm, based on the geometric surface of the electrode. Voltage can vary widely, e.g., from 0,5 to 400, preferably from 2 50 volts.
  • the electrolysis is preferably conducted at room temperature. However, it is also possible to effect the electrolysis at lower or elevated temperatures, even at the boiling temperature of the reaction mixture.
  • the starting steroids can have one or more carboncarbon multiple bonds.
  • Examples of such isolated multiple bonds are endocyclic double bonds, for example, in the l( l)-, 4(5)-, 5(10)-, 5(6)-, 8(9)-,9(l1)- and/or l4-position.
  • the multiple bonds can also be exocyclic, e.g., as a methylene group in, for example, the 1-, 6- and/or l6-position, or as an alkinyl group, e.g., in the l7-position.
  • a A'-double bond is likewise stereospecifically hydrogenated in accordance with the process of this invention. If more than one such multiple bond is present in the steroid molecule, they are hydrogenated independently of one another.
  • the process of this invention has the advantage that the aromatic A-ring which is sometimes present in steroids is not concomitantly reduced.
  • a carbonyl group, which may be present in the steroid molecule also is not attacked.
  • isolated double bonds, such as the A-, 11 11 A-, A- or A -double bond, which do not lead to a center of asymmetry, are also reduced.
  • a preferred class of starting steroids are those having an aromatic A-ring and preferably also a free, etherified or esterified 3-hydroxy group, or an isolated A-double bond, preferably in combination with a 3-keto group or a free, esterified or etherified 3-hydroxy group.
  • the angular methyl groups at the 18- and/or l9-position can be present or absent or replaced by another lower-alkyl group, e.g. ethyl.
  • a methyl group can also be present at any of the available positions of the steroid nucleus, e.g., i, 2, 6, 7, 9, 12 and/or 16 positions.
  • Functional groups e.g., hydroxy or keto, can be present at, for example, the 6, 7, ll, l2, 16 and/or 20-position, hydroxy or acyloxy, preferably acetoxy, can be present, e.g., at the 6-, 7-, 17- and/or 20- positions.
  • a halogen atom e.g., Cl or F
  • Other functional groups e.g., oxide, can also be present in the molecule, e.g., in the 16,17-position.
  • An especially preferred class of starting steroids are A-ring aromatic 3,17-oxygenated steroids of the estrane series having at least one isolated multiple bond,
  • the oxygen function in the 3-position is preferably hydroxy, alkoxy, e.g., of 1-4 carbon atoms, or acyloxy, preferably alkanoyloxy, e.g., of 2-8 carbon atoms
  • the oxygen function in the l7-position is preferably B- hydroxy, B-acyloxy, keto, flalkynyl-Ha-hydroxy, B- acetyl-a-hydroxy, B-acetyl-a-acyloxy, B-hydroxy-acetyl-a-hydroxy, B-acyloxyacetyl-a-hydroxy or B-acyloxyacetyl-a-acyloxy.
  • the starting steroid bears an acyloxy group
  • the exact nature thereof is not critical and can be aliphatic, aromatic, alicyclic or heterocyclic and can be free ofother functional groups or can bear one or more such groups, e.g., hydroxy, carboxy, amido, cyano, halo, etc.
  • acyl group is that of an alkanoic acid of 1-18, preferably 2-l2 carbon atoms, e.g., acetic and undecylic, ofa cycloalkanoic or cycloalkylalkanoic acid, e.g., cyclohexyl-carboxylic acid B-cyclopentyl-propionic acid, of a carbocyclic aryl acid of 612 carbon atoms and having l-2 separate or fused rings, e.g., benzoic, p-toluic, a-naphthoic, or a carbocyclic aralkyl acid of 7-12 carbon atoms, e.g., phenylacetic, of a heterocyclic acid of 5-12 carbon atoms and l-2 heteroatoms, e.g., pyridine-Z-carboxylic acid, thiophene-Z-carboxylic acid, furane-Z-carbox
  • the acyl radical can also be that of a sulfonic or other acyloxy acid, e.g., benzenesulfonic, p-toluenesulfonic, methanesulfonic and ethanesulfonic acid.
  • a sulfonic or other acyloxy acid e.g., benzenesulfonic, p-toluenesulfonic, methanesulfonic and ethanesulfonic acid.
  • the process of this invention has the advantage that the hydrogenation can be conducted under normal pressure with a low expenditure in appartus and additionally can be designed as a continuous process by using electrolytical cells of the tube reactor or filter pressing type (see, for reference, Electro-Organic Chemical Processing by Charles L. Mantell, Noyes Dev. Corp., Parkridge, N. 1., U.S.A., 1968 or Organic Electrochemistry by Manuel M. Baizer, Marcel Dekker Inc., N.Y., 1973).
  • l3-ethyl-3-methoxy-8- isogona-l ,3,S( l0)-trien-l7,B-ol (U-S.P. 3,407,217), for example, is obtained from 13-ethyl-3-methoxy-8- isogona-l,3,5(l0)-trien-l7B-one by reduction of the l7-oxo group with sodium borohydride in methanol.
  • EXAMPLE 1 1.0 g. of 3-methoxy-l,3,5(l0),8-estratetraen-l7B-ol is dissolved in ml. of ethanol and electrolyzed at room temperature in a divided cell (glass diaphragm), after the addition of 5 ml. of concentrated sulfuric acid, for 6 hours at 0.75 A on a Raney nickel electrode. After the reaction mixture has been worked up, 1.0 g. of a colorless reaction product is isolated which, according to analysis by gas chromatography, contains, in
  • EXAMPLE 2 0.5 g. of 3-methoxy-1,3,5(l0), 8-estratetraen-17B-ol is dissolved in 100 ml. of isopropanol and 20 ml. of tetrahydrofuran and, after the addition of 20 ml. of 15 percent perchloric acid was electrolyzed for 3 hours at about 1.0A at room temperature on a palladinised platinum electrode in a cell divided by a cation exchanger. After the reaction mixture has been worked up, the product is 0.48 g. of Sa-estradiol methyl ether in the form of colorless crystals, m.p. 65 C. (methanol).
  • EXAMPLE 3 1.0 g. of 3-methoxy-l,3,5(l0), 9(11)-estratetraen- 1713-01 in 80 ml. of ethanol is heated, together with 10 ml. of concentrated hydrochloric acid, to the boiling point and electrolyzed at the boiling temperature of the mixture (about 80 C.) for 2 hours on a palladinised platinum electrode in a cell divided by a cation exchanger. After the mixture has been worked up, 0.95 g. of 8B-estradiol methyl ether is obtained, melting after chromatography and recrystallization in benzenepetroleum ether, at 100-101 C.
  • EXAMPLE 4 0.05 g. of 3-methoxy-l,3,5(10),6,8,l4-estrahexaen- 175-01 is electrolyzed in 7.5 ml. of ethanol and 2.5 ml. of 10 percent sulfuric acid for 6 hours at room temperature in a divided cell on a palladinised palladium electrode. After working the reaction mixture up as described in Example 1, the product is 3-methoxy- 1,3,5(10),6,8-estrapentaen-l4a-H-173-01, m.p. 144-145 C.
  • EXAMPLE 5 0.5 g. of 3-methoxy-l8-methyl-l,3,5(10),8-estratetraen-l7-one is electrolyzed in 100 ml. of propanol and 30 ml. of dioxane with 20 ml. of percent hydrobromic acid at room temperature for 6 hours on a palladinised copper electrode in a cell divided by a clay diaphragm. After the mixture has been worked up, the yield is 0.48 g. of 3-methoxy-l8-methyl-1,3,5(10)-8aestratrien-l 7-one, m.p. 9293 C., in addition to 0.065 g. of unreacted starting material.
  • EXAMPLE 6 1.0 of 3-methoxy-l7B-acetoxy-18-methyl- 1,3,5(10),8,14-estrapentaene in 150 ml. of ethanol is electrolyzed for 7 hours at room temperature with ml. of 10 percent sulfuric acid in a cell divided by a glass frit material on a palladinised gold electrode. After the reaction mixture has been worked up in accordance with Example 1, the product is 0.61 g. of 3- methoxy-l7B-acetoxy-l8-methyl-1,3,5(l0)-8a,14aestratriene, in addition to 0.36 g. of 3-methoxy-18- methyl-1,3,5(10)-8a,l4a-estratrien-17fi-ol.
  • EXAMPLE 7 0.1 g. of 3B-hydroxy-l7B-benzoyloxy-androst-S-ene is electrolyzed in 80 ml. of ethanol and 20 ml. of tetrahydrofuran with 50 ml. of 5 percent sulfuric acid at 80 C. for 2.5 hours in a cell divided by a cation exchanger diaphragm on a palladinised platinum electrode.
  • the reaction product consists, according to analysis by gas chromatography and NMR, of 0.09 g. of BB-hydroxyl7B-benzoyloxy-5a-androstane in addition to 0.01 g of 5a-androstane'3,l7B-diol.
  • EXAMPLE 8 0.05 g. of 3-methoxy-l7B-hydroxy-l6-methylene- 1,3,5(10)-estratriene in 50 ml. of ethanol and 10 ml. of tetrahydrofuran is electrolyzed with 20 ml. of 10% hydrobromic acid for 2.5 hours in a cell divided by a cation exchanger diaphragm on a palladinised palladium electrode. After working up the reaction mixture analogously to Example 1, 0,04 g. of 3-methoxy-l 7B- hydroxy-16B-methyl-1,3,5( l0)estratriene is obtained, m.p. 116 C.
  • EXAMPLE 9 0.10 g. of 3-methoxy-17B-hydroxy-l7a-ethinyll,3,S(lO)-estratriene is electrolyzed in 25 ml. of etha n01 and 20 ml. of tetrahydrofuran with 5 ml. of 10 percent sulfuric acid for 3 hours in a cell divided by a cation exchanger diaphragm on a palladinised palladium electrode. After the reaction mixture has been worked up, 0.08 g. of 3methoxy-l7fi-hydroxy-l7a-ethyl- 1,3,5(10)-estratriene is obtained, m.p. 180 C.
  • EXAMPLE 10 0.1 g. of a mixture, approximately 1:1, of 6-ethoxycarbonylmethyl- 1 ,3,5( 10 ),6-estratetraene-3 l 7B-diol and 6-ethoxycarbonylmethy1ene'l ,3,5( l0)-estratriene- 3,17B-diol in 25 ml. of ethanol and 10 ml. of tetrahy drofuran is electrolyzed with 10 ml. of 1 percent sulfuric acid for 5 hours on a palladinised platinum electrode in a cell divided by a glass frit material. After the reaction mixture has been worked up. 0.07 g. of 6B- ethoxycarbonylmethyl-1,3,5( 10 )-estratriene-3 l die] is isolated.
  • EXAMPLE 11 0.1 g. of 3-hydroxy-l7B-hydroxy-17a (butin-1-yl)- 1,3,5(10)-estratriene is electrolyzed in 25 ml. of ethano! and 20 m1. of tetrahydrofuran with 5 ml. of 10 percent sulfuric acid in a cell divided by a cation exchanger diaphragm on a palladinised platinum electrode until 1 equivalent of hydrogen has been absorbed. After the reaction mixture has been worked up, 0.09 g. of 3-hydroxy-l7fl-hydroxy-l7a(cis-buten-lyl)- 1,3,5(10)estratriene is obtained, m.p. 120 C.
  • a process for the stereospecific selective electrolytic hydrogenation of a carbon-carbon, non-aromatic multiple bond of an unsaturated steroid having an aromatic ring and which is reducible to a mixture of stereoisomers, while leaving the aromatic ring intact which comprises subjecting an acidic solution of the unsaturated steroid to electrolysis in a divided cell employing a cathode whose surface is a finely divided metal hydrogenation catalyst until the carbon-carbon multiple bond is hydrogenated.
  • a process according to claim 1 wherein the finely divided metal catalyst is nickel, platinum or palladium.
  • the starting steroid is an unsaturated steroid of the estrane series having an aromatic A-ring
  • the finely divided metal catalyst is nickel, platinum or palladium and the reaction is conducted in an aqueous organic solvent acidified with a mineral acid.
  • cathode is catalytically inert platinum as support coated with finely divided palladium in catalytically active form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Steroid Compounds (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
US466172A 1973-05-04 1974-05-02 Electrocatalytic hydrogenation process Expired - Lifetime US3925173A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2323091A DE2323091A1 (de) 1973-05-04 1973-05-04 Elektrokatalytisches hydrierverfahren

Publications (1)

Publication Number Publication Date
US3925173A true US3925173A (en) 1975-12-09

Family

ID=5880272

Family Applications (1)

Application Number Title Priority Date Filing Date
US466172A Expired - Lifetime US3925173A (en) 1973-05-04 1974-05-02 Electrocatalytic hydrogenation process

Country Status (7)

Country Link
US (1) US3925173A (ja)
JP (1) JPS5030860A (ja)
CH (1) CH591406A5 (ja)
DE (1) DE2323091A1 (ja)
FR (1) FR2228060B1 (ja)
GB (1) GB1472119A (ja)
NL (1) NL7405877A (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082627A (en) * 1977-05-26 1978-04-04 Eli Lilly And Company Electrolytic reduction of dihydrobenzopyranoxanthenones
US4326932A (en) * 1976-12-31 1982-04-27 Lever Brothers Company Hydrogenation
WO1993002230A1 (en) * 1991-07-17 1993-02-04 Ayers William M Electrocatalytic hydrogenation of nitriles to amines
US20070000788A1 (en) * 2003-03-05 2007-01-04 Idemitsu Kosan Co., Ltd Organic compound hydrogenation apparatus and method for hydrogenating organic compound
US20130087451A1 (en) * 2011-10-06 2013-04-11 Hitachi, Ltd. Membrane Electrode Assembly and Organic Hydride Manufacturing Device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3469008A (en) * 1966-04-02 1969-09-23 Schering Ag Medicinal compositions which contain 15,16beta-methylene steroids of the 19 nor-androstane series
US3814711A (en) * 1971-07-26 1974-06-04 Mallinckrodt Chemical Works 10-acetamido-s-triazolo-(3,4-a)-isoquinolines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3469008A (en) * 1966-04-02 1969-09-23 Schering Ag Medicinal compositions which contain 15,16beta-methylene steroids of the 19 nor-androstane series
US3814711A (en) * 1971-07-26 1974-06-04 Mallinckrodt Chemical Works 10-acetamido-s-triazolo-(3,4-a)-isoquinolines

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326932A (en) * 1976-12-31 1982-04-27 Lever Brothers Company Hydrogenation
US4399007A (en) * 1976-12-31 1983-08-16 Lever Brothers Company Hydrogenation
US4082627A (en) * 1977-05-26 1978-04-04 Eli Lilly And Company Electrolytic reduction of dihydrobenzopyranoxanthenones
WO1993002230A1 (en) * 1991-07-17 1993-02-04 Ayers William M Electrocatalytic hydrogenation of nitriles to amines
US5266731A (en) * 1991-07-17 1993-11-30 Reilly Industries Electrocatalytic hydrogenations of nitriles to amines
US20070000788A1 (en) * 2003-03-05 2007-01-04 Idemitsu Kosan Co., Ltd Organic compound hydrogenation apparatus and method for hydrogenating organic compound
US7846319B2 (en) * 2003-03-05 2010-12-07 Idemitsu Kosan Co., Ltd. Organic compound hydrogenation apparatus and method for hydrogenating organic compound
US20130087451A1 (en) * 2011-10-06 2013-04-11 Hitachi, Ltd. Membrane Electrode Assembly and Organic Hydride Manufacturing Device

Also Published As

Publication number Publication date
DE2323091A1 (de) 1974-11-21
FR2228060B1 (ja) 1978-08-04
FR2228060A1 (ja) 1974-11-29
NL7405877A (ja) 1974-11-06
GB1472119A (en) 1977-05-04
CH591406A5 (ja) 1977-09-15
JPS5030860A (ja) 1975-03-27

Similar Documents

Publication Publication Date Title
CA1037027A (en) 18-methyl-19-nor-20-keto-pregnanes and process for preparing them
US3925173A (en) Electrocatalytic hydrogenation process
CN1912192A (zh) 一种7-酮石胆酸的制备方法
CA1181717A (en) Electrochemical dehydrogenation of steroidal .delta. su3,5 xx enol ethers under basic conditions to provide steroidal .delta. su4,6 xx dienones
US3444059A (en) Electrolytic reduction of cyclopentanophenanthrene derivatives
Kwok et al. C-19 Functional Steroids. III. 1 2, 19-Disubstituted Androstane and Cholestane Derivatives2
US3506549A (en) Electrolytic reduction of cyclopentanophenanthrene derivatives
US4050998A (en) Electrolytic reduction of aromatic steroids
US3444057A (en) Electrolytic reduction of aromatic steroids
US3720694A (en) Partial electrochemical reduction of 19-nor-delta 1,3,5(10)-steroids
US3702334A (en) Process for the preparation of 17-substituted-delta4-gonenes and intermediates
Faul et al. Side-chain transformations and deuterium labeling in the steroidal sapogenin series
CA1055881A (en) Electrolytic reduction of aromatic steroids
US3515719A (en) 7-methyl-6,19-epoxy steroids of the androstane series
WAWZONEK Electroorganic Syntheses
US3700670A (en) Process for making delta**5 (10)-estrenes or pregnenes and products obtained there
US3657288A (en) Cyclobutanones and process for the preparation thereof
Chen Estrane derivatives—I
Maekawa et al. Selective Dimerization by Paired Electrolysis of Enol Acetate.
DE1593501C3 (de) 15,16 beta-Methylensteroide der 19-Nor-androstan-Reihe, Verfahren zu deren Herstellung sowie diese enthaltende Mittel
US3843499A (en) Production of 4-endotricyclo(5,2,1,02,6-endo)decylamine
Van Moorselaar et al. Investigations on sterols XXIV: Synthesis of some 6‐dehydro‐8α, 10α‐steroid hormone analogues and conversion of 8β, 10α‐into 8α, 10α‐steroids
JPS6237386A (ja) ケトンの電気合成方法
US3264329A (en) Process for preparing 4-hydroxy-3-keto-5alpha-steroids and ethers of 3-hydroxy-delta3-5alpha-steroids intermediates therein
US3839420A (en) 16,17-seco-delta4 and delta5(10)steroids